Transformed Lymphoma: Clinical Trials

10 trials for Transformed Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 4 unknown, 2 completed. 10 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 210Recruiting 4, Unknown 4, Completed 2
Phase 14Unknown 3, Recruiting 1

Follow Transformed Lymphoma: new trials by email Literature Review of Transformed Lymphoma trials Research Report on Transformed Lymphoma

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
POLA-R-CHP in the First-line Treatment of Transformed DLBCL
POLA-R-CHP - Transformed Lymphoma
Phase 2RecruitingFudan University202025-02-172025-02-25
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Acalabrutinib - Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2RecruitingJonsson Comprehensive Cancer Center242023-01-232026-03-10
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) - B-Cell Lymphoma, B Acute Lymphoblastic Leukemia
Phase 2RecruitingJohn Lister302022-04-192025-01-13
DALY II USA/ MB-CART2019.1 for DLBCL
zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine - Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma
Phase 2RecruitingMiltenyi Biomedicine GmbH3152021-05-252026-07-13
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang302021-03-312021-03-15
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
Camrelizumab, Apatinib - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang332020-07-232021-03-15
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang1402020-04-242022-04-14
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Rituximab, Etoposide, Vincristine - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 2UnknownInstitute of Hematology & Blood Diseases Hospital, China1182019-01-212022-01-26
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
Zydelig - Non Hodgkin Lymphoma, Follicular Lymphoma
Phase 2CompletedUniversity of Maryland, Baltimore172017-10-232025-06-27
Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma
Rituximab 375 mg/m2 - Non-Hodgkin's Lymphoma, Diffuse Large Cell Lymphoma
Phase 2CompletedStanford University351997-11-012014-09-15

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (7)  ·  Lymphoma, B-Cell (3)  ·  Lymphoma, Mantle-Cell (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Pyloric Stenosis, Hypertrophic (3)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Lymphoma (2)  ·  Lymphoma, B-Cell, Marginal Zone (2)  ·  Lymphoma, Follicular (2)  ·  Recurrence (2)  ·  Burkitt Lymphoma (1)  ·  Central Nervous System Neoplasms (1)  ·  Waldenstrom Macroglobulinemia (1)

Broader conditions

Hemic and Lymphatic Diseases (8)  ·  Immune System Diseases (8)  ·  Immunoproliferative Disorders (8)  ·  Lymphatic Diseases (8)  ·  Lymphoproliferative Disorders (8)  ·  Neoplasms (8)  ·  Neoplasms by Histologic Type (8)  ·  Lymphoma (6)  ·  Lymphoma, B-Cell (5)  ·  Lymphoma, Non-Hodgkin (5)  ·  Disease Attributes (4)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Digestive System Diseases (3)  ·  Gastric Outlet Obstruction (3)

Interventions

Rituximab (3)  ·  Cyclophosphamide (2)  ·  Lenalidomide (2)  ·  Automobiles (1)  ·  Bendamustine Hydrochloride (1)  ·  Cisplatin (1)  ·  Cytarabine (1)  ·  Dexamethasone (1)  ·  Doxorubicin (1)  ·  Etoposide (1)  ·  R-CHOP protocol (1)  ·  Receptors, Chimeric Antigen (1)  ·  Vincristine (1)  ·  acalabrutinib (1)  ·  apatinib (1)

Sponsors

Huiqiang Huang (3)  ·  Fudan University (1)  ·  Institute of Hematology & Blood Diseases Hospital, China (1)  ·  John Lister (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Miltenyi Biomedicine GmbH (1)  ·  Stanford University (1)  ·  University of Maryland, Baltimore (1)

Countries

China (5)  ·  United States (5)  ·  Canada (1)

Top investigators

Caspian Oliai, MD (1)  ·  Dehui Zou, Dr. (1)  ·  Huiqiang Huang, Professor (1)  ·  Jean Yared, MD (1)  ·  Johanna Theruvath, MD (1)  ·  John Lister, MD (1)  ·  Sandra J Horning, MD (1)  ·  Yizhen Liu, M.D., Ph.D. (1)

Results publications

PMID 12907446